Tiger Pharmaceuticals: Net profit is expected to increase by 105%-204% year-on-year in 2025.

Tiger Pharmaceuticals announced that it is expected to have a net profit attributable to shareholders of the listed company of 830 million to 1.23 billion yuan by 2025, an increase of 105% to 204% compared to the same period last year. The performance change is mainly due to a significant increase in non-recurring gains and losses during the reporting period, a significant increase in disposal and holding income of non-current financial assets held by the company, as well as the recovery of asset value driven by the recovery of the Chinese innovative drug industry. The number and amount of new signed orders of the company have achieved good growth compared to the same period last year. In 2025, the company's net new order range is expected to be between 9.5 billion and 10.5 billion yuan, compared to 8.42 billion yuan for the same period in 2024.